Commit Biologics

About Commit Biologics

Commit Biologics is a biotech company founded in 2021 as a spin-out from Aarhus University in Denmark. It focuses on developing a novel platform technology called BiCE™ (Bispecific Complement Engaging) to harness the power of the complement system for treating cancer and autoimmune diseases. The company aims to create innovative therapeutics with a unique mechanism of action to redefine treatment options in these areas.

Products & Services

BiCE™ Technology:A platform technology designed to activate the complement system for highly selective killing of tumor cells or cells involved in autoimmune diseases. It uses single domain antibodies to bind complement protein C1q, targeting cells of interest with a novel mechanism of action.

Specialties

Complement System Biology Antibody Development Cancer Treatment Autoimmune Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed Extension T: - FT: Seed Extension	A: 5900000 MR: - FA: €5.5m FAN: 5900000	D: 2025-01-28 FD: 2025-01-28	3 investors
2	RT: Seed T: - FT: Seed	A: 17200000 MR: - FA: €16m FAN: 17200000	D: 2024-05-09 FD: 2024-05-09	2 investors

Seed Extension Latest

2025-01-28

$5.9M

3 investors (Pro only)

Seed 2024-05-09

$17.2M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Janine Schuurman

Molecular immunologist

M

Mikkel Wandahl Pedersen

CEO & CSO

LinkedIn (Pro only)

A

Anker Lundemose

Chair

R

Roderick Verhelst

Principal

J

Jeroen Bakker

Principal

N

Nick Stub Laursen

Head of Discovery & Co-founder

View 22 more team members with Pro

Unlock Full Team Directory

Recent News